|
Phase III study shows VMPT regimen superior to VMP for initial treatment of multiple myeloma |
|
Τρίτη, 12 Οκτώβριος 2010 17:00 |
 |
 |
 |
|
Source: JCO
Area: News
According to research published early online in the Journal of Clinical Oncology, the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide was superior to bortezomib-melphalan-prednisone (VMP) alone in patients with multiple myeloma who are ineligible for autologous stem-cell transplantation.
The phase III study involved a total of 511 patients (with newly diagnosed multiple myeloma) who were randomised to nine cycles of VMPT followed by continuous VT as maintenance, or nine cycles of VMP at the same doses with no additional therapy. The primary end point was progression-free survival. Secondary end points included response rate, time to the first evidence of response, overall surv...
Source: www.medworm.com
|
